PL2914270T3 - Środek do zapobiegania lub polepszania stanu stanowiącego pogorszenie funkcji mózgu - Google Patents
Środek do zapobiegania lub polepszania stanu stanowiącego pogorszenie funkcji mózguInfo
- Publication number
- PL2914270T3 PL2914270T3 PL13850415T PL13850415T PL2914270T3 PL 2914270 T3 PL2914270 T3 PL 2914270T3 PL 13850415 T PL13850415 T PL 13850415T PL 13850415 T PL13850415 T PL 13850415T PL 2914270 T3 PL2914270 T3 PL 2914270T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- agent
- brain function
- improving decline
- decline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012238542 | 2012-10-30 | ||
| EP13850415.4A EP2914270B1 (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
| PCT/JP2013/080053 WO2014069667A1 (en) | 2012-10-30 | 2013-10-30 | Agent for preventing or improving decline in brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2914270T3 true PL2914270T3 (pl) | 2022-03-14 |
Family
ID=50627559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13850415T PL2914270T3 (pl) | 2012-10-30 | 2013-10-30 | Środek do zapobiegania lub polepszania stanu stanowiącego pogorszenie funkcji mózgu |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10905705B2 (enExample) |
| EP (1) | EP2914270B1 (enExample) |
| JP (1) | JP6166786B2 (enExample) |
| AU (1) | AU2013339058B2 (enExample) |
| CA (1) | CA2889109C (enExample) |
| ES (1) | ES2906614T3 (enExample) |
| NZ (1) | NZ707081A (enExample) |
| PL (1) | PL2914270T3 (enExample) |
| WO (1) | WO2014069667A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014069667A1 (en) | 2012-10-30 | 2014-05-08 | Kyowa Hakko Bio Co., Ltd. | Agent for preventing or improving decline in brain function |
| US11583546B2 (en) * | 2014-04-30 | 2023-02-21 | Kyowa Hakko Bio Co., Ltd. | Administration of citicoline to improve cognitive performance, attentional performance, and motor function |
| ES2985104T3 (es) | 2016-10-06 | 2024-11-04 | Kyowa Hakko Bio Co Ltd | Cristal de citidina difosfato colina y procedimiento de producción del mismo |
| JP7142284B2 (ja) * | 2017-06-06 | 2022-09-27 | 株式会社らいむ | 神経伸長促進剤 |
| JP2019218284A (ja) * | 2018-06-18 | 2019-12-26 | オンガネジャパン株式会社 | 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5304796A (en) * | 1995-03-06 | 1996-09-23 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| US20010056068A1 (en) | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| US20060046982A1 (en) * | 2004-08-26 | 2006-03-02 | Waugh William H | Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease |
| WO2009096505A1 (ja) * | 2008-01-30 | 2009-08-06 | Kyowa Hakko Bio Co., Ltd. | 注意集中力向上剤 |
| JP2012517421A (ja) * | 2009-02-11 | 2012-08-02 | ライカ ラブズ リミテッド | リポソームシチコリン注射薬 |
| ES2345802B1 (es) * | 2009-03-30 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus. |
| WO2014069667A1 (en) | 2012-10-30 | 2014-05-08 | Kyowa Hakko Bio Co., Ltd. | Agent for preventing or improving decline in brain function |
-
2013
- 2013-10-30 WO PCT/JP2013/080053 patent/WO2014069667A1/en not_active Ceased
- 2013-10-30 NZ NZ707081A patent/NZ707081A/en unknown
- 2013-10-30 CA CA2889109A patent/CA2889109C/en active Active
- 2013-10-30 JP JP2015538829A patent/JP6166786B2/ja active Active
- 2013-10-30 ES ES13850415T patent/ES2906614T3/es active Active
- 2013-10-30 US US14/435,984 patent/US10905705B2/en active Active
- 2013-10-30 PL PL13850415T patent/PL2914270T3/pl unknown
- 2013-10-30 EP EP13850415.4A patent/EP2914270B1/en active Active
- 2013-10-30 AU AU2013339058A patent/AU2013339058B2/en active Active
-
2020
- 2020-12-30 US US17/138,742 patent/US11738037B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2889109C (en) | 2020-09-01 |
| WO2014069667A1 (en) | 2014-05-08 |
| EP2914270B1 (en) | 2022-01-12 |
| US20210113601A1 (en) | 2021-04-22 |
| AU2013339058B2 (en) | 2017-09-07 |
| EP2914270A4 (en) | 2016-03-16 |
| EP2914270A1 (en) | 2015-09-09 |
| JP6166786B2 (ja) | 2017-07-19 |
| US20150306125A1 (en) | 2015-10-29 |
| JP2015535241A (ja) | 2015-12-10 |
| AU2013339058A1 (en) | 2015-05-07 |
| US11738037B2 (en) | 2023-08-29 |
| CA2889109A1 (en) | 2014-05-08 |
| US10905705B2 (en) | 2021-02-02 |
| ES2906614T3 (es) | 2022-04-19 |
| NZ707081A (en) | 2019-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2855478T (pt) | D-tartarato de ledipasvir | |
| IL235905B (en) | Software agent for core layer security | |
| EP2808681A4 (en) | breathalyser | |
| EP2939874A4 (en) | HEAD SUPPORT | |
| GB201216649D0 (en) | Agents and methods | |
| GB201208325D0 (en) | Saccharides | |
| ZA201408855B (en) | Flocculation treatment agent | |
| EP2939873A4 (en) | HEAD SUPPORT | |
| ZA201406786B (en) | Anti-malarial agents | |
| GB2504205B (en) | Improvements in vehicles | |
| EP2842561A4 (en) | MEANS FOR OPTIMIZING THE ENTERAL ENVIRONMENT | |
| PL2838352T3 (pl) | Wóz paszowy | |
| ZA201408094B (en) | Anti-malarial agents | |
| PL2914270T3 (pl) | Środek do zapobiegania lub polepszania stanu stanowiącego pogorszenie funkcji mózgu | |
| PL2855230T3 (pl) | Pojazd szynowy | |
| EP2867155A4 (en) | NANOSTRUCTURE COMPRISING FUNCTIONALLY DIFFERENT SIDES | |
| GB2516594B (en) | Bed | |
| GB2508723B (en) | Seat | |
| SG10201500715XA (en) | Composition for Multiple Health Benefits and Methods Thereof | |
| AU344965S (en) | Sideboard | |
| GB201212457D0 (en) | Smart-road-smart-smart-vehicle synergy | |
| AU346846S (en) | Bed | |
| AU342686S (en) | Bed | |
| AU342703S (en) | Bed | |
| AU342296S (en) | Bed |